Article

Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminib

2024-10-02

Abstract excerpt

Chromosomal translocations that fuse the ABL1 gene to BCR and TEL cause human leukemias. Oligomerization and the loss of an inhibitory myristoylation modification lead to unregulated kinase activity of the BCR-ABL and TEL-ABL fusion proteins. ATP-competitive ABL inhibitors, such as imatinib and ponatinib, are effective against both fusion proteins. We discovered that asciminib, an allosteric inhibitor of BCR-ABL t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e2048a9b-e81a-50aa-ae3e-7167fae067eb
DOI: 10.1101/2024.10.02.616342

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminibDOI 10.1101/2024.10.02.616342Read

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.Semantic proximity Read

Structure, Regulation, Signaling, and Targeting of Abl Kinases in CancerSemantic proximity Read

Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminibSemantic proximity Read

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.Semantic proximity Read

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase InterfaceSemantic proximity Read

A novel hyperactive <i>BCR::ABL1</i> <sup> <i>e6a3</i> </sup> variant confers resistance to combined asciminib plus ponatinib therapySemantic proximity Read

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacySemantic proximity Read

Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.Semantic proximity Read

Structure and dynamic regulation of Abl kinases.Semantic proximity Read

Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1.Semantic proximity Read

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.Semantic proximity Read

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cellsSemantic proximity Read